Delisting risk
CytoMed Therapeutics
Develops donor-derived and iPSC-based cell therapies for cancer.
$0.9200
After-hours close0.00 (0.00%)
At close$0.9200(−3.16%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | — | — | — |
| Jun 2026 | — | — | — |
| May 2026 | — | — | — |
| Apr 2026 | — | — | — |
| Mar 2026 | — | — | — |
| Sep 2025 | — | −$0.07 | — |
| Mar 2025 | — | −$0.05 | — |
| Sep 2024 | — | −$0.04 | — |
| Jun 2024 | — | −$0.05 | — |
The latest year is open to everyone — the 17 quarters behind it read with an account. Sign in | |||
| May 2024 | |||
| Mar 2024 | |||
| Sep 2023 | |||
| Jun 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Sep 2022 | |||
| Jun 2022 | |||
| Mar 2022 | |||
| Dec 2021 | |||
| Sep 2021 | |||
| Jun 2021 | |||
| Mar 2021 | |||
| Dec 2020 | |||
| Sep 2020 | |||
| Jun 2020 | |||
| Mar 2020 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 13, 2026 | — | — | — | — | — | — |
| Jun 30, 2026 | — | — | — | — | — | — |
| May 4, 2026 | — | — | — | — | — | — |
| Apr 27, 2026 | — | — | — | — | — | — |
| Mar 31, 2026 | — | — | — | — | — | — |
| Sep 30, 2025 | — | −$0.07 | — | — | $105.7K | — |
| Mar 31, 2025 | — | −$0.05 | — | — | $74.3K | — |
| Sep 30, 2024 | — | −$0.04 | — | — | $83.3K | — |
| Jun 30, 2024 | — | −$0.05 | — | — | $61.0K | — |
The latest year is open to everyone — the 17 quarters behind it read with an account. Sign in | ||||||
| May 6, 2024 | ||||||
| Mar 31, 2024 | ||||||
| Sep 30, 2023 | ||||||
| Jun 30, 2023 | ||||||
| May 1, 2023 | ||||||
| Mar 31, 2023 | ||||||
| Sep 30, 2022 | ||||||
| Jun 30, 2022 | ||||||
| Mar 31, 2022 | ||||||
| Dec 31, 2021 | ||||||
| Sep 30, 2021 | ||||||
| Jun 30, 2021 | ||||||
| Mar 31, 2021 | ||||||
| Dec 31, 2020 | ||||||
| Sep 30, 2020 | ||||||
| Jun 30, 2020 | ||||||
| Mar 31, 2020 | ||||||